Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly's Abemaciclib Hit Leaves It Down But Not Out

Executive Summary

Continuation of Phase III MONARCH 2 study, with no early termination for efficacy, may mean a delay in filing and a tougher competitive outlook against Pfizer's Ibrance and Novartis' ribociclib.

Advertisement

Related Content

Can Lilly's Abemaciclib Overcome Third Place Finish In CDK4/6 Race?
Ibrance Trial Cements CDK4/6 Inhibitors As Standard Of Care In Breast Cancer
Novartis CDK4/6 Profile Boosted But Challenge To Pfizer Rival Uncertain
EU Approval Recommendation Secures Ibrance Domination
A Split Won’t “Make Or Break” Pfizer, CEO Read Says
Lilly Awaits New Rewards For SGLT-2 Diabetes Drug Jardiance
Lilly Teams Up With Boehringer Ingelheim To Boost Abemaciclib
Novartis Oncology Strategy: Focus On The Microenvironment
ASCO Puts A Spotlight On CDK4/6 Category Ahead Of New Competition
Novartis Ups Pace On Ibrance Challenger As Ribociclib Trial Stopped Early

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097100

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel